A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2019
Price : $35 *
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Trametinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 26 Jul 2019 Planned End Date changed from 1 Dec 2019 to 5 Dec 2019.
- 26 Jul 2019 Planned primary completion date changed from 1 Dec 2019 to 5 Dec 2019.
- 22 Mar 2018 Status changed from not yet recruiting to recruiting.